Oncotelic Therapeutics Inc (OTLC)

[mick]

$MATN,OTC DISCLOSURE & NEWS SERVICE,Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19Press Release | 03/02/2020

Mateon Therapeutics Team Publishes a New Peer-Reviewed Oncology Article on the Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients With Relapsed Acute Myeloid LeukemiaPress Release | 12/27/2019

Mateon Therapeutics Announces Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients with Relapsed Acute Myeloid LeukemiaPress Release | 12/23/2019

EdgePoint announces collaboration with iBio CDMO to implement AI/Blockchain driven TrustPoint Vision Technology in its Texas cGMP facilityPress Release | 12/23/2019

iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics ManufacturingPress Release | 12/23/2019
Steven King Named as Prospective CEO of EdgePoint AIPress Release | 12/11/2019

Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/TrabedersenPress Release | 12/02/2019

Mateon Therapeutics to Present New and Updated Data for OT101 (Trabedersen) Activity Against Brain Tumors at the 2019 Society for Neuro-Oncology (SNO) Annual MeetingPress Release | 11/18/2019

Mateon completes its acquisition of PointR Data Inc.Press Release | 11/04/2019
New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain TumorPress Release | 10/23/2019